The amount that a big player might pay for the exclusivity of groundbreaking anti-aging clinical results would depend on a number of factors, including:
* The size and financial resources of the big player
* The potential market for the product
* The likelihood of regulatory approval
* The level of competition in the market
* The perceived value of the exclusivity
In general, big players are willing to pay a premium for exclusivity, especially if they believe that it will give them a competitive advantage. In the case of groundbreaking anti-aging clinical results, the potential market is huge and the likelihood of regulatory approval is high. As a result, a big player could potentially pay hundreds of millions of dollars for exclusivity.
For example, in 2017, Allergan paid $165 million to acquire Galderma's rights to develop and market an anti-aging cream called Rejuveness. Rejuveness was based on a compound called bakuchiol, which is a natural alternative to retinol. The acquisition gave Allergan exclusive rights to bakuchiol in the United States and Canada.
Another example is the acquisition of Deciem by Estee Lauder in 2020. Deciem is a Canadian cosmetics company that is known for its innovative and affordable products. One of Deciem's most popular products is The Ordinary, a line of serums and other skin care products. Estee Lauder paid $281 million for Deciem, which included the rights to The Ordinary.
These examples show that big players are willing to pay a lot of money for exclusivity, especially when it comes to products that have the potential to be blockbusters. If Sirona Biochem's anti-aging compound TFC-1326 is truly groundbreaking, it could be worth hundreds of millions of dollars to a big player.